Molecular basis of primary and secondary resistance to imatinib mesylate
Recently, IMATINffi MESYLATE (IM), a selective Tyrosine Kinase inhibitor, is widely used as a frontline therapy for Chronic Myeloid Leukemia (CML). However, development of resistance to IM either primary or secondary, has emerged as a major obstacle in the successful management of CML patients. De...
| Main Author: | |
|---|---|
| Format: | Monograph |
| Language: | English |
| Published: |
Pusat Pengajian Sains Perubatan
2012
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/55349/1/DR.%20ABDUL%20AZIZ%20BABA.pdf |